Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Mannucci

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Thrombosis Research|March 14, 2000
Alpha(2)-macroglobulin levels are high in adult patients with congenital antithrombin deficiencyA Tripodi, V Chantarangkul, V De Stefano, et al.
Thrombosis and Haemostasis|October 5, 1992
Pharmacokinetic properties of recombinant factor VIII compared with a monoclonally purified concentrate (Hemofil M). The Recombinate Study GroupM Morfini, G Longo, A Messori, et al.
British Journal of Haematology|December 21, 2000
Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermediaM D Cappellini, L Robbiolo, B M Bottasso, et al.
Neurology|November 24, 2004
Value of Hu antibody determinations in the follow-up of paraneoplastic neurologic syndromesA Lladó, P Mannucci, A F Carpentier, et al.
Clinical Genetics|October 27, 1998
Three novel PROC gene lesions causing protein C deficiencyP J Hallam, P Mannucci, A Tripodi, et al.
Journal of Thrombosis and Haemostasis : JTH|October 7, 2009
Pharmacokinetics and safety of fibrinogen concentrateM J Manco-Johnson, D Dimichele, G Castaman, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 22, 2011
Presurgical pharmacokinetic analysis of a von Willebrand factor/factor VIII (VWF/FVIII) concentrate in patients with von Willebrand's disease (VWD) has limited value in dosing for surgeryJ Di Paola, S Lethagen, J Gill, et al.
Bulletin of the World Health Organization|January 1, 1995
Modern treatment of haemophiliaE Berntorp, V Boulyjenkov, D Brettler, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 29, 2009
Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIIIM Recht, L Nemes, M Matysiak, et al.
Lupus|August 15, 2020
Evaluation of belimumab treatment in patients with systemic lupus erythematosus in a clinical practice setting: Results from a 24-month OBSErve study in ArgentinaA Babini, A M Cappuccio, C Caprarulo, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Thrombosis Research|March 14, 2000
Alpha(2)-macroglobulin levels are high in adult patients with congenital antithrombin deficiencyA Tripodi, V Chantarangkul, V De Stefano, et al.
Thrombosis and Haemostasis|October 5, 1992
Pharmacokinetic properties of recombinant factor VIII compared with a monoclonally purified concentrate (Hemofil M). The Recombinate Study GroupM Morfini, G Longo, A Messori, et al.
British Journal of Haematology|December 21, 2000
Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermediaM D Cappellini, L Robbiolo, B M Bottasso, et al.
Neurology|November 24, 2004
Value of Hu antibody determinations in the follow-up of paraneoplastic neurologic syndromesA Lladó, P Mannucci, A F Carpentier, et al.
Clinical Genetics|October 27, 1998
Three novel PROC gene lesions causing protein C deficiencyP J Hallam, P Mannucci, A Tripodi, et al.
Journal of Thrombosis and Haemostasis : JTH|October 7, 2009
Pharmacokinetics and safety of fibrinogen concentrateM J Manco-Johnson, D Dimichele, G Castaman, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 22, 2011
Presurgical pharmacokinetic analysis of a von Willebrand factor/factor VIII (VWF/FVIII) concentrate in patients with von Willebrand's disease (VWD) has limited value in dosing for surgeryJ Di Paola, S Lethagen, J Gill, et al.
Bulletin of the World Health Organization|January 1, 1995
Modern treatment of haemophiliaE Berntorp, V Boulyjenkov, D Brettler, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 29, 2009
Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIIIM Recht, L Nemes, M Matysiak, et al.
Lupus|August 15, 2020
Evaluation of belimumab treatment in patients with systemic lupus erythematosus in a clinical practice setting: Results from a 24-month OBSErve study in ArgentinaA Babini, A M Cappuccio, C Caprarulo, et al.
Pageof 1